PhD, FISPE
University Medical Center Groningen
University Medical Center Groningen
Groningen, Netherlands
Petra Denig is professor of Drug Utilization Quality in The Netherlands, and heads the section research at the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen. She is also program leader of the ‘’Real world studies in PharmacoEpidemiology, -Genetics, -Economy, &-Therapy” (PEGET) program at the Research Institute GUIDE.
Major research aims are developing innovative strategies and insights that contribute to optimal use of medicines in practice. The focus is on chronic and complex diseases, particularly cardiovascular diseases and diabetes. Her research group combines quantitative and qualitative research methods, and also clinical and patient-reported outcome measures. Prof. Denig and her co-workers have developed educational modules and feedback material for general practitioners and courses on the development of prescribing quality indicators and measuring medication adherence using prescription data.
Prof. Denig is leader of the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT) project, hosting a research database with longitudinal data obtained during routine care from >35.000 patients with type 2 diabetes. GIANTT initiates and facilitates scientific research to assess determinants and quality of drug utilization, to evaluate initiatives for improving the quality of care, and the impact of drug use on patient outcomes in the primary care setting. Furthermore, Prof. Denig is member of the Expertgroup Monitor Prescription Behavior General practitioners, the Working Group Prescription Feedback of the Dutch Institute for Rational Use of Medicine and member of the Medication Adherence Expertise Center of the northern Netherlands (MAECON). She is also expert member for the module Deprescribing of the Dutch Guideline Polypharmacy in the Elderly and member of the steering committee of the Northern European Researchers in Deprescribing (NERD) network.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Thursday, August 25, 2022
2:00 PM – 6:00 PM CEST
Friday, August 26, 2022
5:45 PM – 6:00 PM CEST